S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NASDAQ:HALO

Halozyme Therapeutics - HALO Stock Forecast, Price & News

$43.41
-1.07 (-2.41%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$43.20
$44.44
50-Day Range
$43.09
$51.78
52-Week Range
$31.36
$52.98
Volume
1.43 million shs
Average Volume
1.11 million shs
Market Capitalization
$5.98 billion
P/E Ratio
17.16
Dividend Yield
N/A
Price Target
$53.20

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
22.6% Upside
$53.20 Price Target
Short Interest
Bearish
6.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.88mentions of Halozyme Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
50.00%
From $2.06 to $3.09 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

86th out of 1,122 stocks

Biological Products, Except Diagnostic Industry

11th out of 178 stocks

HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Analysts Set New Price Targets

HALO has been the topic of several analyst reports. The Goldman Sachs Group lifted their target price on shares of Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 26th. StockNews.com downgraded shares of Halozyme Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 11th. Finally, SVB Leerink initiated coverage on shares of Halozyme Therapeutics in a research note on Monday, May 23rd. They issued an "outperform" rating and a $52.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $52.33.

Halozyme Therapeutics Trading Down 2.4 %

NASDAQ:HALO traded down $1.07 during trading hours on Wednesday, hitting $43.41. The company had a trading volume of 1,435,768 shares, compared to its average volume of 1,111,055. The company has a market capitalization of $5.98 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.67 and a beta of 1.20. The stock has a 50-day moving average price of $46.71 and a 200 day moving average price of $41.89. Halozyme Therapeutics has a 52 week low of $31.36 and a 52 week high of $52.98. The company has a debt-to-equity ratio of 3.91, a current ratio of 2.72 and a quick ratio of 2.23.

Halozyme Therapeutics (NASDAQ:HALO - Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.06. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The business had revenue of $152.37 million for the quarter, compared to analysts' expectations of $156.00 million. During the same quarter in the previous year, the business posted $0.63 earnings per share. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. On average, equities research analysts predict that Halozyme Therapeutics will post 2.06 EPS for the current fiscal year.

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

Halozyme Therapeutics Inc - Stock News
Halozyme Delivers for Big Money
Halozyme Completes Antares Pharma Acquisition
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
8/09/2022
Today
8/17/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
145
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$53.20
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+22.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$402.71 million
Pretax Margin
47.87%

Debt

Sales & Book Value

Annual Sales
$443.31 million
Cash Flow
$2.02 per share
Book Value
$2.13 per share

Miscellaneous

Free Float
134,610,000
Market Cap
$5.98 billion
Optionable
Optionable
Beta
1.20

Social Links


Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 59)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.65M
  • Dr. Michael J. LaBarre Ph.D. (Age 58)
    Chief Technical Officer
    Comp: $779.55k
  • Ms. Nicole LaBrosse (Age 39)
    CFO & Director
  • Ms. Tram Bui
    VP of Investor Relations & Corp. Communications
  • Mr. Mark Snyder Esq.
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Mr. Todd Butler
    Chief of Staff to the CEO, VP & Head of Project Management
  • Dr. Christopher Bryant Ph.D. (Age 61)
    Chief Manufacturing Officer & Head of Technical Operations













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2022?

4 brokers have issued 1-year price objectives for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $60.00. On average, they predict the company's share price to reach $53.20 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2022?

Halozyme Therapeutics' stock was trading at $40.21 at the beginning of the year. Since then, HALO stock has increased by 8.0% and is now trading at $43.41.
View the best growth stocks for 2022 here
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.06. The biopharmaceutical company had revenue of $152.37 million for the quarter, compared to analysts' expectations of $156 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 101.73% and a net margin of 75.11%. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 earnings per share.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided earnings per share guidance of $2.10-$2.25 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of $655.00 million-$685.00 million, compared to the consensus revenue estimate of $610.87 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (4.62%), William Blair Investment Management LLC (3.31%), Macquarie Group Ltd. (1.83%), Loomis Sayles & Co. L P (1.57%), Northern Trust Corp (1.56%) and Victory Capital Management Inc. (1.30%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $43.41.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.98 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.53 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 145 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
When was Halozyme Therapeutics founded?

Halozyme Therapeutics was founded in 1998.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.